Karla Lingard
Overview
Explore the profile of Karla Lingard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Wu M, Shepherd S, Fendler A, Carr E, Au L, Harvey R, et al.
Cancer Cell
. 2023 Apr;
41(5):821-823.
PMID: 37116490
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
2.
Spain L, Coulton A, Lobon I, Rowan A, Schnidrig D, Shepherd S, et al.
Cancer Discov
. 2023 Mar;
13(6):1364-1385.
PMID: 36977461
Significance: Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research autopsy and dense sampling of metastases combined with extensive multiomic profiling, our study elucidates the many...
3.
Fendler A, Shepherd S, Au L, Wu M, Harvey R, Wilkinson K, et al.
Cell Rep Med
. 2022 Oct;
3(10):100781.
PMID: 36240755
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the...
4.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Schmitt A, et al.
Cancer Cell
. 2022 Apr;
40(4):438.
PMID: 35413273
No abstract available.
5.
Fendler A, Au L, Shepherd S, Byrne F, Cerrone M, Boos L, et al.
Nat Cancer
. 2022 Feb;
2(12):1321-1337.
PMID: 35121900
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were...
6.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Byrne F, et al.
Nat Cancer
. 2022 Feb;
2(12):1305-1320.
PMID: 35121899
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated...
7.
Fendler A, Shepherd S, Au L, Wu M, Harvey R, Schmitt A, et al.
Lancet
. 2022 Jan;
399(10328):905-907.
PMID: 35090602
No abstract available.
8.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Schmitt A, et al.
Cancer Cell
. 2021 Dec;
40(2):114-116.
PMID: 34968417
No abstract available.
9.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Byrne F, et al.
Nat Cancer
. 2021 Dec;
2:1321-1337.
PMID: 34950880
CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered...
10.
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, et al.
Cancer Cell
. 2021 Oct;
39(11):1497-1518.e11.
PMID: 34715028
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the...